Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Enhanced supression of the platelet IIb/IIIa receptor with integrilin therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial (CP Cannon, Chairman, Data Safety Monitoring Board)

The ESPRIT Investigators. Enhanced supression of the platelet IIb/IIIa receptor with integrilin therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial (CP Cannon, Chairman, Data Safety Monitoring Board). Lancet. 2000; 356:2037-44..


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.